All articles tagged with #drug advertising
The FDA issued about 100 warning letters to pharmaceutical companies and healthcare providers, including major drugmakers and telehealth firms, to stop or modify misleading drug advertisements, signaling an aggressive regulatory push despite concerns over resource limitations.
The FDA has issued multiple warning letters to pharmaceutical companies, including Eli Lilly and Novo Nordisk, for misleading drug advertisements across various media, emphasizing concerns over safety disclosures and the portrayal of drugs in a way that may mislead consumers, as part of a broader crackdown on deceptive marketing practices in the industry.
The FDA has begun cracking down on telehealth companies like Hims & Hers for promoting unapproved and misleading versions of prescription drugs, including weight loss medications, as part of a broader effort to ensure truthful pharmaceutical advertising. The agency sent over 100 cease and desist letters to companies making false claims, highlighting concerns over online drug promotion and advertising practices that may mislead consumers about drug safety and efficacy.
FDA Commissioner Martin Makary criticized Hims & Hers' Super Bowl ad for violating federal law by promoting weight-loss drugs without discussing potential side effects, highlighting concerns over misleading direct-to-consumer pharmaceutical advertising and a decline in FDA enforcement actions.
President Trump has signed a memorandum to revive a 1990s-era policy that would significantly restrict prescription drug advertising on television, potentially impacting pharmaceutical revenues and major networks that rely on such advertising.